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Abstract
Coccidioides is a soil-dwelling fungus that causes coccidioidomycosis, a disease also
known as Valley fever, which affects humans and a variety of animal species. Recent find-
ings of Coccidioides in new, unexpected areas of the United States have demonstrated the
need for a better understanding of its geographic distribution. Large serological studies on
animals could provide important information on the geographic distribution of this pathogen.
To facilitate such studies, we used protein A/G, a recombinant protein that binds IgG anti-
bodies from a variety of mammalian species, to develop an enzyme immunoassay (EIA)
that detects IgG antibodies against Coccidioides in a highly sensitive and high-throughput
manner. We showed the potential of this assay to be adapted to multiple animal species by
testing a collection of serum and/or plasma samples from dogs, mice, and humans with or
without confirmed coccidioidomycosis. We then evaluated the performance of the assay in
dogs, using sera from dogs residing in a highly endemic area, and found seropositivity rates
significantly higher than those in dogs of non-endemic areas. We further evaluated the spec-
ificity of the assay in dogs infected with other fungal pathogens known to cross-react with
Coccidioides. Finally, we used the assay to perform a cross-sectional serosurvey investigat-
ing dogs from Washington, a state in which infection with Coccidioides has recently been
documented. In summary, we have developed a Coccidioides EIA for the detection of anti-
bodies in canines that is more sensitive and has higher throughput than currently available
methods, and by testing this assay in mice and humans, we have shown a proof of principle
of its adaptability for other animal species.
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Introduction
Coccidioidomycosis, also known as Valley fever, is a fungal disease caused by the soil-dwelling
fungi Coccidioides immitis or C. posadasii. The disease has been characterized as endemic to
the arid regions of southwestern United States, Mexico, Central America, and South America
[1, 2]. Humans and a variety of mammalian species, including dogs, cats, horses, South Ameri-
can camelids, and marine mammals [3–7], can be infected when aerosolized arthroconidia
(asexual spores) are inhaled. Although the precise ecological niche of Coccidioides remains
unknown, it is widely accepted that the fungus grows in soil as hyphae and produces infective
arthroconidia that become airborne upon soil disturbance [8–10].
Much of the work that mapped Coccidioides to the southwestern United States was derived
from skin testing studies, which test for the presence of a delayed-type hypersensitivity
response to Coccidioides indicating previous exposure. These studies were conducted in the
1940-50s on people who had no or limited reported travel outside of known endemic areas
[11–14]. In addition, skin testing studies were performed on cattle as a sentinel species for
human cases [15]. This approach was based on the assumption that animals travel considerably
less than humans, and that exposure rates of a given area will reflect the presence of Cocci-
dioides in that geographic area.
More recently, studies have used the gold-standard assay for antibody detection, agar gel
immunodiffusion (AGID), to investigate dogs as a sentinel species for human cases [16]. Both
prevalence and incidence of Coccidioides exposure in dogs were assessed in southern Arizona,
an area known to be highly endemic for coccidioidomycosis [16]. In addition, dogs have been
used in California and Texas to model the spatial distribution of Coccidioides and identify
areas of high risk exposure for humans [17, 18].
Notably, recent findings demonstrating the presence of Coccidioides in the Pacific North-
west, specifically south central Washington, have challenged our current understanding of
where this fungus resides and have highlighted the need to generate more accurate distribution
maps [19–21]. Although surveillance methods that involve skin testing or serological assays
that detect Coccidioides exposure in humans are available [11, 22, 23], it is becoming increas-
ingly difficult to find people with limited travel history between known and unknown endemic
areas. Testing animals susceptible to coccidioidomycosis may help to better understand the
geographic distribution of this disease; however, few assays are available for testing animals.
To date, there is no assay for detecting Coccidioides antibodies that is high-throughput, highly
sensitive, and adaptable to a variety of animal species.
AGID is a highly specific test that can detect both IgM and IgG antibodies against Cocci-
dioides in a variety of host species [22]; however, this method is time-consuming and is not
suitable for large-scale surveillance studies. Conversely, EIAs are more sensitive, have a higher
throughput, and can generate results in less than two hours compared to AGID, which
requires 24–48 hours for incubation [24]. However, the main limitation of existing Cocci-
dioides EIAs is that most of them are limited to detection in humans. The only reported study
that used EIA for detection of anti-Coccidioides antibodies in animals other than humans is a
report by Catala´n-Dibene et al., who developed and field tested an EIA for testing rodents,
using a mouse-specific secondary antibody. In addition, Durkin et al. developed a Coccidioides
antigen EIA that can be applied to multiple host species [25], but a later investigation using
this assay in dogs found antigen detection to be an insensitive method as compared to anti-
body detection [26].
In this study, we report the use of conjugated fusion protein A/G to develop an EIA that
can detect antibodies against Coccidioides in a variety of animal species that are susceptible to
coccidioidomycosis. Protein A/G is a recombinant protein capable of binding IgG antibodies
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from many animal species including dogs, cats, mice, rats, horses, alpacas, and rabbits. Previ-
ous studies have shown its multi-species use in immunoassays for detection of Toxoplasma
gondii and Borrelia spp. [27–29]. For this assay, we demonstrated adaptability to dogs by test-
ing serum samples from dogs with coccidioidomycosis and other endemic fungal infections, as
well as from dogs residing in known endemic and non-endemic areas. We also performed a
cross-sectional serosurvey investigating dogs in Washington, an area where burden of disease
remains unclear and prevalence of Coccidioides exposure in dogs or any other animal species
has not been investigated.
Materials and methods
Human and animal sera
All sera and/or plasma for the development and evaluation of this assay were residual speci-
mens acquired from existing collections. No animal or human specimens were collected spe-
cifically for this project. All sera was shipped to the Centers for Disease Control and
Prevention (CDC) frozen and stored for varying times at room temperature (RT), 4˚C, and
-80˚C.
Sera for assay development. Canine sera positive for coccidioidomycosis (n = 37), blasto-
mycosis (n = 10), and histoplasmosis (n = 10) were residual sera from anonymous specimens
received after routine reference clinical testing at MiraVista Diagnostics Laboratory (Indianap-
olis, IN, USA). Residual murine plasma from C57BL/6 mice vaccinated with the attenuated
Coccidioides and the uninfected controls were acquired from an unrelated study by the Univer-
sity of Arizona. Negative control sera from mice and healthy dogs residing in non-endemic
areas were purchased from BioreclamationIVT (Chestertown, MD, USA). Human sera were
from known Coccidioides seropositive and seronegative specimens from CDC collected under
CDC IRB protocol exemption #4013, and consisted of anonymized sera collected as part of
CDC public health surveillance efforts.
Sera for assay evaluation. To evaluate assay performance, we used sera from dogs that
resided in known endemic regions of southern Arizona, sera from dogs that resided in non-
endemic regions (S1 Table), and sera from dogs who resided in the newly identified endemic
region Washington. Remnant dog sera from Arizona (n = 212) were received from a previous
study by the Rickettsial Zoonosis Branch, CDC, which were obtained in three counties
(Cochise, Santa Cruz, and Yuma) located near the U.S.-Mexico border. Serum was collected
by rabies clinics, animal control centers, and animal humane societies. Information collected
on the dogs included, age group (<1, 1–5, 6+ years), size (small, <20; medium, 20–55; large,
56+ pounds), county of residence (Cochise, Yuma, Santa Cruz), and ownership status (stray/
free-roaming or owned/relinquished by the owner).
Samples from non-endemic areas (n = 663) were donated by two centers, Kansas State Uni-
versity (KSU) Veterinary Diagnostic Laboratory (Manhattan, KS, USA) and North Carolina
State University (NCSU) College of Veterinary Medicine (Raleigh, NC, USA), and represented
36 states (S1 Table), all thought to be non-endemic for coccidioidomycosis. Serum was submit-
ted by local providers for rabies (KSU) or tick-borne diseases (NCSU) diagnostic testing and
surveillance and found to be seronegative for both. For both studies, history of travel to
endemic areas for Coccidioides was not collected.
From Washington, remnant serum from dogs (n = 1041) obtained during routine veteri-
nary examination was received from 18 veterinary clinics across the state with 88.8% (924/
1041) of samples collected from the eastern arid regions of Washington. Clinics were asked to
provide available residual serum samples and a residential zip code associated with the dog.
A Coccidioides antibody EIA for dogs and other mammalian species
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Samples were collected during both routine healthy check-ups and during examinations for a
variety of medical conditions.
Protein A/G Coccidioides antibody EIA
The new protein A/G Coccidioides antibody EIA for the detection of IgG antibodies employed
the use of the antigen coated plates from the OMEGA Coccidioides Antibody Enzyme Immu-
noassay (IMMY; Norman, OK, USA). This product was chosen over other commercially avail-
able products because the kit provides two separate plates for detection of IgG antibody (CF
antigen-coated plate) and IgM antibody (TP antigen-coated plate) as compared to other kits
that combine CF and TP antigen into one plate for simultaneous detection of IgG and IgM
antibodies. The sensitivity of the assay should be improved using antigen coated plates that
detects predominately IgG, as protein A/G does not bind to IgM.
Assay procedure. The manufacturer’s assay procedure was followed with the following
exceptions: only the CF antigen-coated 96-well plate was used for antibody detection and EIA
kit conjugate was substituted with a recombinant peroxidase conjugated protein A/G (Thermo
Fisher Scientific, Rockford, IL, USA) for antibody detection. To perform the assay, 100 μl of
the kit positive control, calibrator control, and animal serum diluted with the kit specimen dil-
uent was added to the respective microwells of the CF antigen-coated plate. After a 30-min
incubation at RT, microwells underwent three washes with the kit’s wash buffer using an
ELx50 Microplate Strip Washer (BioTek, Winooski, VT, USA). After three washes, excess
wash buffer was removed by striking the plate multiple times on paper towels. Protein A/G
was diluted with the kit specimen diluent, and added to the microwells and left to incubate for
30 min. Three washes were performed again followed by striking the plate multiple times on
paper towels, and 100 μl of the kit TMB substrate was then added to the microwells. After a
10-min incubation, 100 μl of the kit stop solution was added to each microwell and the optical
density of each well was read at 450 nm with Molecular Devices SpectraMax 250 Microplate
Reader (GMI, Ramsey, MN, USA). EIA units were calculated by normalizing the OD value of
each sample by the OD value of the kit calibrator control. Thus, a sample with an EIA unit
equal to 1.00 had an OD value equal to that of the calibrator.
Determination of optimal dilutions for protein A/G and sera. To determine the optimal
concentration of the conjugated protein A/G for use in the EIA, serial 2-fold dilutions of pro-
tein A/G (1:10,000 to 1:80,000) were assayed against serially diluted Coccidioides or Histo-
plasma reagent control anti-sera developed for the use in AGID. At all protein A/G dilutions
between 1:10,000 and 1:80,000, the results of the EIA assay were able to distinguish Cocci-
dioides from Histoplasma when the AGID control anti-sera was diluted at 1:100 (S2 Table).
The largest difference in EIA units was observed when using protein A/G at a dilution of
1:10,000; therefore, we chose this dilution for the remainder of the study. Next, we found the
optimal serum dilution for this assay in dogs and mice to be 1:25 (S3 Table).
Agar Gel Immunodiffusion (AGID)
AGIDs for detection of IgG antibodies against Coccidioides immunodiffusion complement
fixation (IDCF) antigen was performed according to IMMY’s protocol using the Coccidioides
Immunodiffusion reagents from IMMY. Specifically, Coccidioides IDCF Antigen (IMMY)
and Coccidioides IDCF Positive Control (IMMY) were plated on precast Cleargel agar plates
(IMMY). Plates were incubated in a humidified chamber at RT, and results were assessed in
72 hours.
A Coccidioides antibody EIA for dogs and other mammalian species
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Data analysis
ROC curve analysis (performed using SigmaPlot 11.2, Sysat Software, Inc., San Jose, CA, USA)
was used to determine the cutoff for the protein A/G EIA assay. Fisher exact chi-square test
was used to compare proportions of dogs positive for IgG antibodies against Coccidioides from
Arizona, Washington, and non-endemic areas. Simple logistic regression was used to compare
the odds of testing positive for Cocci between geographic regions. Two sample t-test was used
to compare mean EIA values between infected and healthy dog and mouse samples. Wilcoxon
rank-sum test was used to compare median EIA values for human isolates, due to small sample
size for human data. Exact McNemar’s test was used to compare the difference in dependent
proportions from EIA and AGID tests. Univariable and multivariable logistic regression analy-
ses were used to investigate the risk factors related to seropositivity. Statistical analyses were
conducted using (SAS v. 9.4, SAS Institute, Cary, NC, USA). All p-values correspond to
2-sided tests, unless otherwise stated, and p-values of 0.05 or less were considered to indicate
statistical significance.
Results
Use of protein A/G allows for detection of IgG antibodies against
Coccidioides in multiple species
We first assessed whether the protein A/G Coccidioides antibody EIA was able to detect IgG
antibodies against Coccidioides from multiple mammalian species. Fig 1 demonstrates the
assay’s ability to distinguish between healthy and Coccidioides-infected mice (p< 0.01), dogs
(p< 0.001), and humans (p = 0.057).
Development of the protein A/G EIA for Coccidioides using sera from
naturally infected dogs
The cutoff value of the protein A/G Coccidioides antibody EIA was determined by Receiver
Operating Characteristic (ROC) curve analysis, a method that graphs sensitivity (true positive
frequency) versus 1 –specificity (false positive frequency) across varying cutoffs in the unit
square. Serum obtained from healthy dogs residing in non-endemic areas (n = 25) and from
Fig 1. Detection of IgG antibodies against Coccidioides from multiple mammalian species using protein
A/G. EIA units from healthy and Coccidiodes-infected mouse, dog, and human sera/plasma samples. The y-axis
is split with a scale of 0–1.5 EIA units and of 1.5–20 EIA units.
https://doi.org/10.1371/journal.pone.0175081.g001
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dogs with a confirmed diagnosis of coccidioidomycosis (n = 37) was analyzed. The estimated
area under the ROC curve was found to be 0.97 (95% confidence interval (CI) = [0.93, 1.01],
standard error = 0.02, p<0.001), indicating a high degree of diagnostic accuracy for the protein
A/G Coccidioides antibody EIA (Fig 2). The cutoff value of 1.33 EIA units yielded a high degree
of sensitivity and specificity for the assay and thus was used as the cutoff for the rest of our
analysis.
At this cutoff value, 24 of 25 serum samples from healthy dogs tested negative for IgG anti-
bodies against Coccidioides, for a specificity of 96.0% (95% CI = [86.3, 100], Table 1). Of the
serum samples from dogs diagnosed with coccidioidomycosis, 35 of 37 tested positive for a sen-
sitivity of 94.6% (95% CI = [81.8, 99.3], Table 1). Samples were also analyzed by AGID and
compared to the protein A/G EIA (Table 2); agreement between the two assays was found to be
90.0% (56/62). By AGID, 30 of 37 serum samples from dogs diagnosed with coccidioidoymcosis
Fig 2. ROC curve analysis shows a high degree of diagnostic accuracy for the assay. Sensitivity and
1-Specificity were plotted for healthy dogs (n = 25) and dogs confirmed with coccidioidomycosis (n = 37).
Estimated area under the curve (A) is 0.97.
https://doi.org/10.1371/journal.pone.0175081.g002
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tested positive for a sensitivity of 81.1% (95% CI = [64.8, 92.0]). All 25 serum samples from
healthy dogs tested negative by AGID for a specificity of 100% (95% CI = [86.3, 100]). Compar-
ing the EIA and AGID assays by an exact McNemar’s test resulted in a p-value of 0.014, thereby
concluding that the tests are significantly different.
To assess cross-reactivity of antibodies against other endemic fungal pathogens, we tested
serum samples from dogs clinically diagnosed with two other diseases caused by dimorphic
fungi (Table 3), histoplasmosis (n = 10) and blastomycosis (n = 10). For serum samples from
dogs with confirmed histoplasmosis, 9 (90.0%) tested negative for IgG antibodies against Coc-
cidioides. For serum samples from dogs with confirmed blastomycosis, all 10 tested negative.
Use of the protein A/G EIA for veterinary testing of known and newly
identified endemic regions
Using the protein A/G EIA, we estimated the prevalence of anti-Coccidioides antibodies among
dogs from two states, one with a known level of endemnicity (Arizona) and another with an
unknown level (Washington), as well as dogs from non-endemic areas. Of dogs residing in
Arizona, 43/212 (20.3%) tested positive for IgG antibodies against Coccidioides (Table 4). In
contrast, 30/663 (4.5%) of control dogs from non-endemic regions tested positive (Table 4).
Arizona dogs had a significantly higher odds of testing positive compared to dogs from non-
endemic areas (OR = 5.37, 95% CI = [3.27, 8.82], p<0.001, Table 4). The proportion of Arizona
dogs that had antibodies against Coccidioides was higher among free-roaming or stray dogs
(24/68; 30.8%) than those that were owned or relinquished by the owner (19/111; 14.6%).
Dogs that were free-roaming or stray had increased odds of testing positive compared to
dogs who were owned or relinquished by their owner (OR = 2.59, 95% CI = [1.19, 5.66],
p-value < 0.001), (Table 5). On univariable analysis, the other potential risk factors examined:
age group, size, and county of residence were not significantly associated with seropositivity in
dogs (Table 5). Furthermore, there were no significant interactions between ownership status
and these other characteristics. On multivariable logistic regression analysis, after adjusting for
age, OR for positivity increases to 2.86 (95% CI = [1.38, 5.93], p-value < 0.001).
To determine seropositive rates of dogs in Washington, serum from dogs (n = 1041) col-
lected from 18 veterinary clinics within the state of Washington were tested and 30/1041
(2.9%) tested positive for antibodies to Coccidioides (Table 4). While dogs tested in Arizona
have significantly higher odds of being positive, compared to non-endemic states, dogs tested
in Washington did not have a significantly higher odds of testing positive for antibodies to
Coccidioides compared to dogs from non-endemic areas (OR = 0.63, 95% CI = [0.37, 1.05],
Table 4).
Discussion
Identifying areas of geographic risk for acquiring an infection with Coccidioides is essential for
healthcare providers and public health professionals to promptly identify persons with Valley
Table 1. Corresponding table for ROC curve analysis.
EIA diagnosis Confirmed diagnosis Cutoff Area under the curve Sensitivity % (95% CIa) Specificity % (95% CI)
Positive Negative
Positive 35 1 1.33 0.97 94.6 (81.8, 99.3) 96.0 (86.3, 100)
Negative 2 24
a Confidence Interval
https://doi.org/10.1371/journal.pone.0175081.t001
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Table 2. Comparison of AGID and EIA results for dog sera from confirmed coccidioidomycosis cases
and healthy controls.
Cases (n = 37) AGID result EIA result EIA units
1 + + 19.84
2 + + 16.77
3 + + 16.44
4 + + 16.40
5 + + 15.34
6 + + 14.85
7 + + 14.20
8 + + 13.72
9 + + 13.55
10 - + 12.76
11 + + 12.71
12 + + 12.11
13 + + 10.56
14 + + 10.49
15 + + 9.85
16 + + 9.31
17 + + 9.02
18 + + 7.18
19 + + 6.75
20 + + 5.30
21 + + 4.89
22 + + 3.95
23 + + 3.68
24 + + 3.21
25 - + 3.17
26 + + 2.90
27 + + 2.84
28 + + 2.82
29 - + 2.77
30 - + 2.68
31 + + 2.68
32 + + 2.12
33 + + 1.91
34 - + 1.79
35 + + 1.34
36 - - 0.65
37 - - 0.38
Controls (n = 25) AGID result EIA result EIA units
1 - + 1.33
2 - - 1.23
3 - - 1.18
4 - - 0.90
5 - - 0.90
6 - - 0.76
7 - - 0.71
8 - - 0.67
(Continued )
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fever. However, the available maps of endemic regions were developed in the 1940-50s by per-
forming skin testing on cattle and people who had not left their county of birth and are likely
outdated [14]. Replicating such methods in today’s more mobile population would be chal-
lenging. Therefore, additional methods, such as targeted environmental sampling and regional
veterinary surveillance, are needed to identify the current geographic range of Coccidioides.
Table 2. (Continued)
9 - - 0.67
10 - - 0.66
11 - - 0.59
12 - - 0.58
13 - - 0.58
14 - - 0.54
15 - - 0.51
16 - - 0.40
17 - - 0.40
18 - - 0.40
19 - - 0.37
20 - - 0.30
21 - - 0.29
22 - - 0.28
23 - - 0.26
24 - - 0.17
25 - - 0.10
(+) and (-) represent positive and negative tests results, respectively.
https://doi.org/10.1371/journal.pone.0175081.t002
Table 3. Sensitivity and specificity of EIA in dogs.
Total Positive Negative
Sensitivity 37 35 (94.6%) 2 (5.4%)
Specificity 25 1 (4%) 24 (96%)
Cross-Reactivity with Histoplasma 10 1 (10%) 9 (90%)
Cross-Reactivity with Blastomyces 10 0 (0%) 10 (100%)
Positive and negative rates were assessed for healthy dogs (n = 25), dogs with confirmed coccidioidomycosis (n = 37), blastomycosis (n = 10), and
histoplasmosis (n = 10).
https://doi.org/10.1371/journal.pone.0175081.t003
Table 4. Comparison of EIA reactivity in sera from dogs residing in endemic (Arizona), non-endemic, and newly endemic (Washington) areas.
Positive Negative ORa (95% CIb)
Arizona (n = 212) 43 (20.3%) 169 (79.7%) 5.37 (3.27, 8.82)
Washington (n = 1041) 30 (2.9%) 1011 (97.1%) 0.63 (0.37, 1.05)
Non-endemic states (n = 663) 30 (4.5%) 633 (95.5%) Ref c
a Odds ratio
b Confidence Interval
c Reference
https://doi.org/10.1371/journal.pone.0175081.t004
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In an effort to contribute to updating Coccidioides distribution maps, we developed and val-
idated an EIA that is capable of detecting IgG antibodies against Coccidioides that is sensitive,
high-throughput, and adaptable to testing multiple mammals, including dogs. We demon-
strated that a cutoff value of 1.33 EIA units for testing dog sera provided a high degree of sensi-
tivity and specificity that were comparable to the reported rates for the original OMEGA
Coccidioides Antibody Enzyme Immunoassay (IMMY) [30]. The assay was also highly specific
with minimal signal detected from healthy controls, and animals with confirmed Blastomyces
and Histoplasma infections. Specifically, of 20 animals with known Histoplasma and Blasto-
myces infections tested with our assay, only one cross-reacted with Coccidioides. However, this
was not unexpected as cross-reactivity between Coccidioides, Histoplasma, and Blastomyces
antigens has been reported previously (32, 33).
Of the control dogs residing in non-endemic areas for Coccidioides, 4.5% tested positive.
This low level may be a result of cross-reactivity with Blastomyces and Histoplasma, which are
endemic to the areas from which non-endemic sera were obtained. Alternatively, since history
of travel for these dogs was unknown, it is possible that some of the seropositive dogs traveled
into endemic regions and were exposed to Coccidioides. Recording travel history may improve
the sensitivity of future surveys.
From our investigation of dogs with antibodies against Coccidioides from known endemic
areas of the United States, we observed that in the endemic area of southern Arizona, 20.3%
of tested dogs possessed antibodies against Coccidioides, as compared to 4.5% of dogs from
the non-endemic area. In a similar cross-sectional study of southern Arizona dogs (4–18
months old) using AGID for detection, Shubitz et al. found 8% (32/381) of tested dogs to be
positive for antibodies against Coccidioides [16]. The higher positivity proportion of 20.3% in
our study is likely attributed to the greater sensitivity of EIAs compared to AGID. Other
studies investigating risk factors associated with Coccidioides infection in dogs, identified
Table 5. Comparison of characteristics between Arizona dogs with positive and negative presence of IgG antibodies.
Characteristics Positive N (%) Total n = 43 (100%) Negative N (%) Total n = 168 (100%) Unadjusted Odds Ratio (95% CIa)
Age (years)
<1 8 (25.0) 24 (75.0) Ref b
1–5 28 (18.9) 120 (81.1) 0.70 (0.29–1.72)
6 7 (22.6) 24 (77.4) 0.88 (0.27–2.80)
Ownership Statusc
Owned/Relinquished by Owner 19 (14.6) 111 (85.4) Ref
Stray/Free-Roaming 24 (30.8) 54 (69.2) 2.59 (1.31–5.15)
Size
Small (<20 pounds) 10 (15.4) 55 (84.6) Ref
Medium (20–55 pounds) 18 (22.8) 61 (77.2) 1.62 (0.69–3.82)
Large (56+ pounds) 15 (22.4) 52 (77.6) 1.59 (0.66–3.85)
County
Cochise 6 (15.4) 33 (84.6) Ref
Yuma 18 (25.7) 52 (74.3) 1.90 (0.69–5.29)
Santa Cruz 19 (18.6) 83 (81.4) 1.26 (0.46–3.43)
Characteristics of age (years), ownership status, size, and county were assessed in Arizona dogs.
Four observations were omitted from analysis due to missing data.
a Confidence interval
b Reference
c 3 Dogs were missing Ownership Status
https://doi.org/10.1371/journal.pone.0175081.t005
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increased risk in dogs that were kept outside and/or roamed on large areas of land (Butkie-
wicz et al., 2005). Similar to those studies, we found that dogs that were free-roaming or
strays had a higher positive rate than owned or relinquished dogs which also suggests that
more prolonged or intense time spent outdoors may increase Coccidioides exposure. The
agreement between results obtained from different investigations further validate utility of
our test for dog surveillance.
We investigated seropositivity rates of dogs residing in Washington where locally acquired
cases have recently been identified. We found the seropositivity rate to be comparable between
Washington dogs and dogs residing in other, non-endemic areas, thereby concluding that the
degree of Coccidioides exposure in Washington dogs is low. These results showed that although
locally-acquired human cases of coccidioidomycosis have occurred in Washington, the
regional background IgG seropositive rate of this convenience survey was lower than an estab-
lished endemic area. Continued surveillance could help track whether the range of Coccidioides
expands or becomes more prevalent in areas of Washington. Based on our results from the
Arizona population and previous studies, future studies might target stray or free-roaming
dogs in contrast to this serosurvey that predominately tested sera from owned dogs visiting
veterinary clinics.
One limitation of the assay is that it only detects IgG antibodies against Coccidioides in that
protein A/G does not bind to IgM antibodies. Given that IgM antibodies against Coccidioides
are associated with the initial antibody response during early primary infection [22] while IgG
antibodies develop afterwards and persist longer as IgM levels wane, surveillance projects
using the assay developed here would miss early acute Coccidioides infections. However, for
the purpose of our study, the detection of IgG is more informative compared to IgM, as IgG
levels are more likely to correlate with the previous exposure. Similarly, Shubitz et al. looked at
both IgG and IgM antibodies against Coccidioides by AGID in dogs residing in Arizona and
concluded that the shorter window of host IgM production and lower concentration of circu-
lating IgM antibodies make it difficult to detect early Coccidioides infections with serological
assays [16].
Finally, this assay can be used as a tool in investigating and mapping the expansion of the
endemic region for coccidioidomycosis. We have validated the protein A/G EIA for Cocci-
dioides detection in dogs, and demonstrated a proof of principle of its adaptability for other
animal species. In the future, cutoff values for other species will need to be determined so that
this method may be adopted for large serological studies in other mammals whose IgG anti-
bodies are recognized by protein A/G, such as horses, cattle, cats, and others.
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